2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2024-10-3-0-33504Genetics<strong>Circulating platelet-derived microRNAs as potential biomarkers of STEMI in patients with hypertension</strong><strong>Circulating platelet-derived microRNAs as potential biomarkers of STEMI in patients with hypertension</strong>ZhelankinAndrey V.ZhelankinAndrey V.zhelankin.andrey@gmail.comStonoginaDaria A.StonoginaDaria A.stonogina.d@gmail.comAkselrodAnna S.AkselrodAnna S.7402898@mail.ru202410300

Background: Circulating extracellular platelet-derived microRNAs have been actively studied over the last decade as promising biomarkers of cardiovascular disease (CVD), since platelet activation plays a key role in the pathogenesis of CVD. The aim of the study: To compare platelet-derived microRNA profiles in patients with uncomplicated hypertension (HT) and in patients with HT and acute myocardial infarction with ST-segment elevation (STEMI). Materials and methods: The study included 20 patients with uncomplicated HT and 15 patients with HT and STEMI. At least 90% of the participants in each group received antiplatelet therapy. A blood sample was collected from each patient in a CTAD anticoagulant tube and blood plasma was obtained by two-step centrifugation. The degree of hemolysis of the plasma samples was determined spectrophotometrically. MicroRNAs were isolated from plasma samples and used for reverse transcription and quantification of relative levels of eight main circulating extracellular platelet-derived microRNAs (miR-223-3p, miR-126-3p, miR-21-5p, miR-24-3p, miR-320a-3p, miR-191-5p, miR-150-5p and miR-23a-3p) by quantitative PCR using the TaqMan Advanced technology (Thermo Fisher Scientific, USA). Normalized relative expression levels for each miRNA were calculated. Differences were considered statistically significant at p &lt; 0.05 (Mann-Whitney test). Results: Patient groups did not differ in age, BMI, platelet count, lipid profile and degree of hemolysis of plasma samples. No differences were found between the ratio of platelet-derived and erythrocyte-derived microRNA between patient groups. No statistically significant differences were found in the relative levels of circulating microRNA between the study groups. Principal component analysis and heatmap analysis of microRNA expression in the samples showed a division of the samples into groups based more on the degree of hemolysis than on the presence/absence of STEMI. Conclusion: In the studied sample of hypertensive patients, the effect of hemolysis of plasma samples on circulating platelet-derived microRNA profiles was more significant than the presence of STEMI

Background: Circulating extracellular platelet-derived microRNAs have been actively studied over the last decade as promising biomarkers of cardiovascular disease (CVD), since platelet activation plays a key role in the pathogenesis of CVD. The aim of the study: To compare platelet-derived microRNA profiles in patients with uncomplicated hypertension (HT) and in patients with HT and acute myocardial infarction with ST-segment elevation (STEMI). Materials and methods: The study included 20 patients with uncomplicated HT and 15 patients with HT and STEMI. At least 90% of the participants in each group received antiplatelet therapy. A blood sample was collected from each patient in a CTAD anticoagulant tube and blood plasma was obtained by two-step centrifugation. The degree of hemolysis of the plasma samples was determined spectrophotometrically. MicroRNAs were isolated from plasma samples and used for reverse transcription and quantification of relative levels of eight main circulating extracellular platelet-derived microRNAs (miR-223-3p, miR-126-3p, miR-21-5p, miR-24-3p, miR-320a-3p, miR-191-5p, miR-150-5p and miR-23a-3p) by quantitative PCR using the TaqMan Advanced technology (Thermo Fisher Scientific, USA). Normalized relative expression levels for each miRNA were calculated. Differences were considered statistically significant at p &lt; 0.05 (Mann-Whitney test). Results: Patient groups did not differ in age, BMI, platelet count, lipid profile and degree of hemolysis of plasma samples. No differences were found between the ratio of platelet-derived and erythrocyte-derived microRNA between patient groups. No statistically significant differences were found in the relative levels of circulating microRNA between the study groups. Principal component analysis and heatmap analysis of microRNA expression in the samples showed a division of the samples into groups based more on the degree of hemolysis than on the presence/absence of STEMI. Conclusion: In the studied sample of hypertensive patients, the effect of hemolysis of plasma samples on circulating platelet-derived microRNA profiles was more significant than the presence of STEMI

microRNAsmyocardial infarctionSTEMIbiomarkershypertensionmicroRNAsmyocardial infarctionSTEMIbiomarkershypertensionСписок литературыLi Z, Lin L, Wu H, et al. Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention. Frontiers in Public Health. 2021;9:559751. DOI: https://doi.org/10.3389/fpubh.2021.559751Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736-1788. DOI: https://doi.org/10.1016/S0140-6736(18)32203-7Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. DOI: https://doi.org/10.1161/CIR.0000000000001123Kringeland E, Tell GS, Midtb&oslash; H, et al. Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland Health Study. European Journal of Preventive Cardiology. 2022;29(1):147-154. DOI: https://doi.org/10.1093/eurjpc/zwab068Konstantinou K, Tsioufis C, Koumelli A, et al. Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. Journal of Clinical Hypertension. 2019;21(8):1135-1143. DOI: https://doi.org/10.1111/jch.13622Bj&ouml;rkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185(10):1630-1645. DOI: https://doi.org/10.1016/j.cell.2022.04.004Mangieri A, Gallo F, Sticchi A, et al. Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. Cardiovascular Intervention and Therapeutics. 2020;35(2):117-129. DOI: https://doi.org/10.1007/s12928-020-00642-wHałucha K, Rak-Pasikowska A, Bil-Lula I. Protective Role of Platelets in Myocardial Infarction and Ischemia/Reperfusion Injury. Cardiology Research and Practice. 2021;2021:5545416. DOI: https://doi.org/10.1155/2021/5545416Fuentes E, Moore-Carrasco R, de Andrade Paes AM, et al. Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(6):509-520. DOI: https://doi.org/10.1177/1074248419861437Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. Journal of Geriatric Cardiology. 2017;14(2):135-150. DOI: https://doi.org/10.11909/j.issn.1671-5411.2017.02.008Kamińska J, Koper OM, Siedlecka-Czykier E, et al. The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of Biological Sciences. 2018;25(7):1263-1271. DOI: https://doi.org/10.1016/j.sjbs.2016.10.015Baidildinova G, Nagy M, Jurk K, et al. Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 2021;8:684920. DOI: https://doi.org/10.3389/fcvm.2021.684920Viereck J, Thum T. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circulation Research. 2017;120(2):381-399. DOI: https://doi.org/10.1161/CIRCRESAHA.116.308434Anfossi S, Babayan A, Pantel K, et al. Clinical utility of circulating non-coding RNAs - an update. Nature Reviews Clinical Oncology. 2018;15(9):541-563. DOI: https://doi.org/10.1038/s41571-018-0035-xZhou SS, Jin JP, Wang JQ, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacologica Sinica. 2018;39(7):1073-1084. DOI: https://doi.org/10.1038/aps.2018.30Kaur A, Mackin ST, Schlosser K, et al. Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovascular Research. 2020;116(6):1113-1124. DOI: https://doi.org/10.1093/cvr/cvz302Melak T, Baynes HW. Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine. 2019;30(2):179-194.Churov A, Summerhill V, Grechko A, et al. MicroRNAs as Potential Biomarkers in Atherosclerosis. International Journal of Molecular Sciences. 2019;20(22):5547. DOI: https://doi.org/10.3390/ijms20225547Schulte C, Barwari T, Joshi A, et al. Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. Circulation Research. 2019;125(3):328-340. DOI: https://doi.org/10.1161/CIRCRESAHA.119.314937Arraud N, Linares R, Tan S, et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. Journal of Thrombosis and Haemostasis. 2014;12(5):614-627. DOI: https://doi.org/10.1111/jth.12554Puhm F, Boilard E, Machlus KR. Platelet Extracellular Vesicles. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(1):87-96. DOI: https://doi.org/10.1161/ATVBAHA.120.314644Zhelankin AV, Iulmetova LN, Sharova EI. The Impact of the Anticoagulant Type in Blood Collection Tubes on Circulating Extracellular Plasma MicroRNA Profiles Revealed by Small RNA Sequencing. International Journal of Molecular Sciences. 2022;23(18):10340. DOI: https://doi.org/10.3390/ijms231810340Gutmann C, Mayr M. Circulating microRNAs as biomarkers and mediators of platelet activation. Platelets. 2022;33(4):512-519. DOI: https://doi.org/10.1080/09537104.2022.2042236Pedersen OB, Grove EL, Kristensen SD, et al. MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease. Thrombosis and Haemostasis. 2022;122(2):181-195. DOI: https://doi.org/10.1055/s-0041-1730375Procyk G, Klimczak-Tomaniak D, Sygitowicz G, et al. Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring. Journal of Clinical Medicine. 2022;11(7):1763. DOI: https://doi.org/10.3390/jcm11071763Krammer TL, Zeibig S, Schrottmaier WC, et al. Comprehensive Characterization of Platelet-Enriched MicroRNAs as Biomarkers of Platelet Activation. Cells. 2022;11(8):1254. DOI: https://doi.org/10.3390/cells11081254Krammer TL, Mayr M, Hackl M. microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring. International Journal of Molecular Sciences. 2020;21(10):E3477. DOI: https://doi.org/10.3390/ijms21103477Sunderland N, Skroblin P, Barwari T, et al. MicroRNA Biomarkers and Platelet Reactivity: The Clot Thickens. Circulation Research. 2017;120(2):418-435. DOI: https://doi.org/10.1161/CIRCRESAHA.116.309303Paseban M, Marjaneh RM, Banach M, et al. Modulation of microRNAs by aspirin in cardiovascular disease. Trends in Cardiovascular Medicine. 2020;30(5):249-254. DOI: https://doi.org/10.1016/j.tcm.2019.08.005Krammer TL, Kollars M, Kyrle PA, et al. Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects. Frontiers in Pharmacology. 2022;13:1078722. DOI: https://doi.org/10.3389/fphar.2022.1078722Czajka P, Fitas A, Jakubik D, et al. MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. Frontiers in Physiology. 2021;12:652579. DOI: https://doi.org/10.3389/fphys.2021.652579Pordzik J, Pisarz K, De Rosa S, et al. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Frontiers in Endocrinology. 2018;9:74. DOI: https://doi.org/10.3389/fendo.2018.00074Garcia A, Dunoyer-Geindre S, Zapilko V, et al. Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator Using Human Haematopoietic Stem Cells. Thrombosis and Haemostasis. 2019;119(2):254-263. DOI: https://doi.org/10.1055/s-0038-1676802Zapilko V, Fish RJ, Garcia A, et al. MicroRNA-126 is a regulator of platelet-supported thrombin generation. Platelets. 2020;31(6):746-755. DOI: https://doi.org/10.1080/09537104.2020.1775804Kaudewitz D, Skroblin P, Bender LH, et al. Association of MicroRNAs and YRNAs With Platelet Function. Circulation Research. 2016;118(3):420-432. DOI: https://doi.org/10.1161/CIRCRESAHA.114.305663Becker KC, Kwee LC, Neely ML, et al. Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. Scientific Reports. 2020;10(1):6169. DOI: https://doi.org/10.1038/s41598-020-63263-6McManus DD, Freedman JE. MicroRNAs in platelet function and cardiovascular disease. Nature Reviews Cardiology. 2015;12:711-717. DOI: https://doi.org/10.1038/nrcardio.2015.101Schulte C, Molz S, Appelbaum S, et al. miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease. PLoS ONE. 2015;10(12):e0145930. DOI: https://doi.org/10.1371/journal.pone.0145930Fourdinier O, Schepers E, Metzinger-Le Meuth V, et al. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific Reports. 2019;9:4477. DOI: https://doi.org/10.1038/s41598-019-41101-8Li S, Guo LZ, Kim MH, et al. Platelet microRNA for predicting acute myocardial infarction. Journal of Thrombosis and Thrombolysis. 2017;44:556-564. DOI: https://doi.org/10.1007/s11239-017-1537-6Liu J, Qin L, Wang Z, et al. Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS. Thrombosis Research. 2020;186:71-74. DOI: https://doi.org/10.1016/j.thromres.2019.12.016Felekkis K, Papaneophytou C. Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases. International Journal of Molecular Sciences. 2020;21(2):561. DOI: https://doi.org/10.3390/ijms21020561Mussbacher M, Krammer TL, Heber S, et al. Impact of Anticoagulation and Sample Processing on the Quantification of Human Blood-Derived microRNA Signatures. Cells. 2020;9(8):1915. DOI: https://doi.org/10.3390/cells9081915Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. DOI: https://doi.org/10.1161/CIR.0000000000000617Appierto V, Callari M, Cavadini E, et al. A lipemia-independent NanoDrop(&reg;)-based score to identify hemolysis in plasma and serum samples. Bioanalysis. 2014;6(9):1215-1226. DOI: https://doi.org/10.4155/bio.13.344Binderup HG, Madsen JS, Heegaard NHH, et al. Quantification of microRNA levels in plasma &ndash; Impact of preanalytical and analytical conditions. PLoS ONE. 2018;13(7):0201069. DOI: https://doi.org/10.1371/journal.pone.0201069Poel D, Buffart TE, Oosterling-Jansen J, et al. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Experimental and Molecular Medicine. 2018;50(3):e454. DOI: https://doi.org/10.1038/emm.2017.288Doss JF, Corcoran DL, Jima DD, et al. A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genomics. 2015;16:952. DOI: https://doi.org/10.1186/s12864-015-2156-2Smith MD, Leemaqz SY, Jankovic-Karasoulos T, et al. Haemolysis Detection in MicroRNA-Seq from Clinical Plasma Samples. Genes. 2022;13(7):1288. DOI: https://doi.org/10.3390/genes13071288Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59(1):S1-6. DOI: https://doi.org/10.1016/j.ymeth.2012.09.015Kirschner MB, Edelman JJB, Kao SCH, et al. The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics. 2013;4:94. DOI: https://doi.org/10.3389/fgene.2013.00094Pizzamiglio S, Zanutto S, Ciniselli CM, et al. A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncology Letters. 2017;13(1):315-320. DOI: https://doi.org/10.3892/ol.2016.5452Zhelankin AV, Stonogina DA, Vasiliev SV, et al. Circulating Extracellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021;11(7):962. DOI: https://doi.org/10.3390/biom11070962Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation Cardiovascular Genetics. 2011;4(4):446-454. DOI: https://doi.org/10.1161/CIRCGENETICS.110.958975